Impact of critical handling errors on delivered budesonide/formoterol dose in dry powder inhalers – An in vitro study

Gunilla Telg (Sodertalje, Sweden), Thomas Lööf, Gunilla Telg, Georgios Stratelis

Source: International Congress 2016 – Pulmonary drug delivery
Session: Pulmonary drug delivery
Session type: Thematic Poster
Number: 971
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Gunilla Telg (Sodertalje, Sweden), Thomas Lööf, Gunilla Telg, Georgios Stratelis. Impact of critical handling errors on delivered budesonide/formoterol dose in dry powder inhalers – An in vitro study. Eur Respir J 2016; 48: Suppl. 60, 971

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Clinical equivalence of budesonide delivered via two dry powder inhalers
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Critical handling errors with dry-powder, metered dose and soft-mist inhaler devices in an observational COPD study
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019


Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001

Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Reliability of inhalation therapy through a multidose dry powder inhaler
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


In vitro testing of two budesonide dry powder inhalers at different flow rates
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products
Source: Eur Respir J 2002; 20: Suppl. 38, 541s
Year: 2002

Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children
Source: Eur Respir J 2001; 18: Suppl. 33, 121s
Year: 2001

A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children
Source: Eur Respir J 2001; 18: Suppl. 33, 121s
Year: 2001

The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)?
Source: Eur Respir J 2005; 26: Suppl. 49, 338s
Year: 2005

Technique training doesn‘t improve patients ability to use pressurised metered dose inhalers (pMDIs)
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009


Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 472s
Year: 2003

Dose delivery characteristics of two dry powder inhalers in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 291s
Year: 2004

Equivalence testing of salbutamol dry powder inhalers by in vitro impaction
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001